



Express Mail No.: **EV452775665US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: D'Amato

Confirmation No.: 6861

Application No.: 10/732,867

Group Art Unit: 1626

Filed: December 9, 2003

Examiner: Saeed, Kamal A.

For: ANALOGS OF 2-
PHTHALIMIDINOGLUTARIC ACID

Attorney Docket No.: 9516-181-999

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A01 to A26, B01 to B12, and C01 to C337** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

The above-identified application is a divisional application of Application No. 09/309,464, filed May 11, 1999, issued as U.S. Patent No. 6,673,828 on January 6, 2004. References are not provided as they are available in the file history of the parent application. However, if the examiner would prefer, copies of any of the references cited herein will be provided upon request.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), Applicants estimate that a fee of \$180.00 is due in connection with the filing of this Information Disclosure Statement. However, should

07/15/2005 SSITHIB1 00000200 503013 10732867

01 FC:1806 180.00 DA

NYJD: 1582188.1

the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,


Date July 12, 2005

by Yeahsil Moon Reg No 52, OK 2 35,203

Anthony M. Insogna (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

 LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.		APPLICATION NO.	
				9516-181-999		10/732,867	
				APPLICANT D'Amato			
				FILING DATE December 9, 2003		GROUP 1626	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	2002/0061923	5/23/02	D'Amato			
	A02	6,020,358	2/1/00	Mullet et al.			
	A03	5,919,790	7/6/99	Allen et al.			
	A04	5,731,325	3/24/98	Andrulis, Jr. et al.			
	A05	5,679,696	10/21/97	Fenton et al.			
	A06	5,654,312	8/5/97	Andrulis, Jr. et al.			
	A07	5,643,915	7/1/97	Andrulis, Jr. et al.			
	A08	5,629,327	5/13/97	D'Amato			
	A09	5,605,914	2/25/97	Muller			
	A10	5,605,684	2/25/97	Piacquadio			
	A11	5,502,066	3/26/96	Heinemann			
	A12	5,443,824	8/22/95	Piacquadio			
	A13	5,434,170	7/18/95	Andrulis, Jr.			
	A14	5,405,855	4/11/95	Andrulis, Jr.			
	A15	5,399,363	3/21/95	Liversidge et al.			
	A16	5,385,901	1/31/95	Kaplan, et al.			
	A17	5,134,127	7/28/92	Stella et al.			
	A18	5,021,404	6/4/91	Folkman, et al.			
	A19	5,001,116	3/19/91	Folkman, et al.			
	A20	4,994,443	2/19/91	Folkman, et al.			
	A21	4,552,888	11/12/85	Koppel, et al.			
	A22	3,705,162	12/5/72	Graudums, et al.			
	A23	3,625,946	12/7/71	Heinrich, et al.			
	A24	3,563,986	2/16/71	Frankus, E.			
	A25	3,560,495	2/2/71	Frankus, E.			
	A26	2,830,991	4/15/58	Keller, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	1,182,709	3/4/70	Austria				
	B02	1 182 709	3/4/70	EP				
	B03	0 325 199	7/26/89	EP				
	B04	0 357 061	3/7/90	EP				
	B05	0 688 771	6/14/95	EP				

B06	58-131978	8/6/83	Japan				
B07	63-119500	5/24/88	Japan				
B08	WO 91/10424	7/25/91	PCT				
B09	WO 92/14455	9/3/92	PCT				
B10	WO 92/18496	10/29/92	PCT				
B11	WO 94/20085	9/15/94	PCT				
B12	WO 95/04533	2/16/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Algire, 1945, "Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants," J. Natl. Cancer Inst. pp. 73-85
C02	Allegri, 1964, "Confermata l'inefficacia della talidomides nella terapia dei tumori," Gazzetta Medica Italiana pp. 124-127
C03	Ambs et al., 1997, "Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression," FASEB J. 11:443-448
C04	Apt, 1965, "Effect of thalidomide on the course of experimental Chagas' Disease," BOI. Chil. Parasitol. 20(3):84-86
C05	Aronson et al., 1984, "Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures," Arch. Dermatol. 120(11):1466-1470
C06	Bach et al., 1963, "Studies on the possible anti-neoplastic effect of thalidomide," ACTA Pathologica ET Microbiologica Scandinavica 59:491-499
C07	Bach et al., 1963, "Thalidomide in cancer chemotherapy," Lancet 1:1271
C08	Bahmer, 1992, "Therapie bei lymphozytischer infiltration," Der Hautarzt 43:663
C09	Balabanova et al., 1992, "Lupus erythematosus hypertrophicus et profundus," Z. Hautkr 67(9):812-815
C10	Barnes. et al., "Tumor Necrosis Factor Production in Patients with Leprosy", <i>Infection and Immunity</i> , Vol. 60 No. 4, pp. 1441-1446 (1992)
C11	Barnhill, et al., "Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various other Conditions", <i>J. Am. Acad. Dermatol.</i> , Vol. 7, No. 3, pp. 317-323-(1982)
C12	Barnhill, R. et al., 1984, "Studies on the Anti-inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytes and Monocytes", <i>J. A& Acad. Derm.</i> , Vol. 11, No. 5, Part 1, pp. 814-819
C13	Barriere, H., "Traitement par la thalidomide", <i>La Presse Med.icale</i> , Vol. 12, No. 15, pp. 963 (1983)
C14	Bazzoli, et al., "The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt", <i>J. Embryol. Exp. Morph.</i> , Vol. 41, pp. 125-135 (1977)
C15	Beck, Jr. et al. "Vascular Development: Cellular and Molecular Regulation", <i>The FASEB Journal</i> , Vol. 11, pp. 365-374 (1997)
C16	Beccerica, E., "L'approccio terapeutico al paziente anziano con artrite reumatoide", <i>Clin. Ter.</i> , Vol. 122, pp. 289-298 (1987)
C17	Belaube, P. et al., 1983, "Should Thalidomide be Rehabilitated?", <i>Sem. Hop. Paris</i> , Vol. 59, No. 45, pp. 3101-3104
C18	Bensinger, W.I., "Supportive Care in Marrow Transplantation", <i>Curr. Opin. Oncol.</i> , Vol. 4, No. 4, pp. 614- 623 (1992)
C19	Bernal, et al., "Cellular Immune Effects of Thalidomide in Actinic Prurigo", <i>Int'l. J. of Dermat.</i> , Vol. 31, No. 8, pp. 599-600 (1992)
C20	Blair, R. et al., "Human Mast Cells Stimulate Vascular Tube Formation", <i>Journal of Clinical Investigation</i> , Vol. 99, NO. 11, pp. 2691-2700 (1997)
C21	Blaschke, V. et al., "Chromatographische Racernattrennung von Thalidomid und teratogene Wirkung der Enantiomere, <i>Arzneimittel Forsch./Dru,q Res.</i> , Vol. 29, No. 11, pp. 1640-1642 (1979)
C22	Bonifacio, J. et al., "A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum", <i>Science</i> , Vol. 2, pp. 79-80 (1990)
C23	Bonnetblanc, et al., "Thalidomide and Recurrent Aphthous Stomatitis: a Follow-up Study", <i>Dermatology</i> , Vol. 193, No. 4, pp. 321-323 (1996)
C24	Boodman, S.G., "Questions About a Popular Prenatal Test", <i>The Washington Post</i> (1992)
C25	Bowers, et al., "Effect of Thalidomide on Orogenital Ulceration", <i>Br. Med. Journ.</i> , Vol. 287,

	No. 6395, pp.799-800 (1983)
C26	Braun et al., 1981, "Thalidomide metabolite inhibits tumor cell attachment to concanavalin a coated surfaces," Biochem. Biophys. Res. Comm. 98(4):1029-1034
C27	Brem et al., 1991, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas," J. Neurosurg. 74:441-446
C28	Bressler et al., 1992, "Clinicopathologic Correlation of occult choroidal neovascularization in age-related macular degeneration," Arch. Ophthalmol. 110:827
C29	Brodthagen, 1985, "Significant response of oral aphthosis to thalidomide treatment," J. Am. Acad. Dermatol. 13(3):509
C30	Brovarone et al., 1991, "Occhio e gravidanza," Minerva Ginecol 43:141-167
C31	Browne et al., 1991, "Expression of recombinant human plasminogen and aglycoplasminogen in HeLa cells," Fibrinolysis 5:257-260
C32	Bubl et al., 1993, "Dysphagia in dermatologic disease," Dysphagia 8(2):85-90
C33	Buckley et al., 1990, "Pyoderma gangrenosum with severe pharyngeal ulceration," J. Royal Soc. Med. 83:590-591
C34	Buelens, 1967, "Treatment of a grade II astrocytoma with thalidomide (Phthalylglutamic acid imide) [Behandlung eines astrocytoms II. Grades mit thaliodmid (N-Phthalylglutaminsaureimid)], Arzneimittel-Forsch., 17(5):646-648
C35	Bullock, 1986, "The clinical significance of erythema nodosum," Hosp. Pract. 21(3):102E-2H, 102K-2L, 102Q-2R pas
C36	Burger et al., 1992, "Epidermolysis bullosa acquisita a rare late complication of allogeneic bone marrow transplantation?" Bone Marrow Transplantation 9(2):139-141
C37	Burrows, 1993, "Thalidomide Modifies disease," Brit. Med. J. 307(6909):939-940
C38	Buckley et al., 1990, "Pyoderma gangrenosum with severe pharyngeal ulceration," J. Royal Soc. Med. 83:590-591
C39	Calnan et al., 1977, "Actinic prurigo (Hutchinson's Summer Prurigo)," Clin. Exp. Dermatol. 2(4):365-372
C40	Cant, J.S., "Minor Ocular Abnormalities Associated With Thalidomide", <i>The Lancet</i> , p. 1134 (1966)
C41	Carmichael, et al., "Thalidomide: A Restricted Role", <i>Lancet</i> , Vol. 339, No. 8805, p. 1362 (1992)
C42	Cashin, C.H. et al., "Angiogenesis and Chronic Inflammation", <i>Agents and Actions</i> , Vol. 34, NO. 314, pp. 332-338 (1991)
C43	Casini, G. et al., "Preparazione Di Uno Degli Antipodi Ottici Della 2-Ftalimimidoglutarimide", <i>Il Farmaco, Ed. Sc.</i> , Vol XIX, F&C. 6, pp. 563-565 (1964)
C44	Chapon, et al., "Neuropathies Caused by Thalidomide", <i>Rev. Neurol.</i> , Vol. 141, No. 11, pp. 719-728 (1985)
C45	Chaudhrv. A. et al., "Effects of Prednisolone and Thalidomide on Induced Submandibular Gland tumors in Hamsters", <i>Canc. Res.</i> , Vol. 26, No. 9, Part 1, pp. 1884-1886 (1966)
C46	Chen. T. et al., "Plasma Pharmacokinetics and Urinary Excretion of Thalidomide after Oral Dosing in Healthy Male Volunteers," <i>The Am. Society for Pharma. andkxPeri. Therapeutics</i> , Vol. 17, No. 4, pp. 402-405 (1988)
C47	Chosidow. O, et al., "Sclerodermatous Chronic Graft-Versus-Host Disease: Analysis of Sevenscases", <i>J. Am. Acad. Dermatol.</i> , Vol. 26, No. 1, pp. 49-55 (1992)
C48	Claydon, et al., "Gastrointestinal Emergencies in HIV Infection", <i>Balliere's Clin Gastroennterol.</i> , Vol. 5, No. 4, pp. 887-911 (1991)
C49	Clemmensen et al., 1984, "Thalidomide neurotoxicity," Arch. Dermatol. 120(3):338-341
C50	Colville-Nash et al., 1992, "Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications," Ann. Rheum. Dis. 51:919-625
C51	Congy, et al., "Plasma Zinc Levels in Elderly Patients Hospitalized in Long Stay Units. Correlations with Other Nutritional Markers, Immunological Tests and Survival", <i>Sem. Hop. Paris</i> , Vol. 59, No. 45, pp. 3105-3108 (1983)
C52	Costa, et al., "Aseptic Adenitis in a Patient with Pyoderma Gangrenosum", <i>Ann. Dermatol.</i> , Vol. 121, No. 8, pp. 550-552 (1994) (Abstract Only)
C53	Crain, E. et al., "The Effect of Thalidomide on Experimental Autoimmune Myasthenia Gravis", <i>J. of Autoimmunity</i> , Vol. 2, pp. 197-202 (1989)
C54	Crawford, C.L., "Letter: Thalidomide in Erythema Nodosum Leprosum", <i>Lancet</i> , Vol. 2, No. 839, pp. 1201-1202 (1973)
C55	Crawford, C.L., "Treatment of Erythema Nodosum Leprosum with Thalidomide," <i>Lancet</i> , Vol. 2, No. 828, pp. 567-568 (1973)
C56	Crawford, C.L., "Use of Thalidomide in Leprosy [letter; comment]", <i>BMJ</i> , Vol. 302, No. 6729, pp. 1603-1604 (1991)
C57	Crum et al., 1985, "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin

		fragment," <i>Science</i> 230:1375-1378
C58		Current Bibliographics in Medicine, "Thalidomide: Potential Benefits and Risks", <i>National Inst. Health, National Library of Medicine</i> pp. 1-72 (Jan. 1963-July 1997)
C59		Dark, et al., "Combretastin A-4, an Agent that Displays Potent and Selective Toxicity Toward Tumor Vasculature", <i>Cancer Research</i> , Vol. 37, pp. 1829-1834 (1997)
C60		David-Bajar, K.M., "Subacute Cutaneous Lupus Erythematosus", <i>J. Invest. Dermatol.</i> Vol. 100, No. 1, pp. 2s-8s (1993)
C61		D'Amato, R. J. et al., "Thalidomide is an Inhibitor of Angiogenesis", <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, pp. 4082-4085 (1994)
C62		D'Amato, et al., "Angiogenesis Inhibition in Age-Related Macular Degeneration", <i>Ophthalmology</i> , Vol. 102, No.9,pp.1261-1262(1995)
C63		D'Amato. et al., "Microscopic Analysis of Retinal-Vessels Utilizing: Fluorescein-Labeled High-Molecular-Weight Dextran," <i>Invest. Ophthalmol. & Visual Science</i> 33(4):1082 (1992)
C64		De et al., 1975, "Possible antineoplastic agents I," <i>J. Pharma. Sci.</i> 64(2):262-266
C65		DeCock, 1979, "Treatment of Ulcerative Colitis," <i>Brit. Med. J.</i> 1:1356
C66		DeKlerk et al., 1969, "New methods of treatment for renal allotransplants using the baboon as a primate experimental model," <i>J. Urol.</i> 102(5):532-540
C67		Dhodapkar et al., "A phase II pilot study of anti-angiogenesis therapy using thalidomide in patients with multiple myeloma," <i>UARK</i> 98-003, pp. 1-15
C68		Dicken, C. H., "Malignant pyoderma", <i>J. of the Am. Acad. of Dermatol.</i> , Vol. 13, No. 6, pp. 1021-1025 (1985)
C69		DiPaolo, et al., "Thalidomide: Effects on Ehrlich Ascites Tumor Cells in vitro", <i>Science</i> , Vol. 144, pp. 1583 (1964)
C70		DiPaolo, 1963, "Effect of thalidomide on a variety of transplantable tumors," <i>Cancer Chemo. Reports</i> , 29:99-102
C71		DiPaolo, 1963, "In vitro test systems for cancer chemotherapy. II. Correlation of in vitroinhibition of dehydrogenase and growth with in vivo inhibition of Ehrlich ascites tumor," <i>P.S.E.B.M.</i> 114:384-387
C72		DiPaolo et al., 1966, "Teratogenesis-oncogenesis: A study of possible relationships," <i>Arch. Pathol.</i> 81:3-23
C73		Dorveaux et al., 1984, "Le traitement actuel du lupus erythemateux chronique," <i>Le Concours Med.</i> 106(31):2957-2961
C74		Doutre et al., 1987, "Pyoderma gangrenosum and hemopathies. A propos of 2 cases," <i>Nouv. Rev. Fr. Hematol.</i> 29(4):251-254
C75		Dunn, et al., "Bone Marrow Transplantation and Cataract Development", <i>Arch. Ophthalmol.</i> Vol. 11 1, No. 10, pp. 1367-1373 (1993)
C76		(Editorial) "Thalidomide in Dermatology and Leprosy", <i>Lancet</i> , Vol. 2, No. 8446, pp. 80-81 (1985)
C77		(Editorial) "Thalidomide Tested for Treatment of AIDS", <i>U.S. Pharm.</i> , Vol. 18, No. 8, p. 14 (1993)
C78		Eger, K. et al., 1990, "Synthesis, Central Nervous System Activity and Teratogenicity of a Homothalidomide," <i>Arzheim. Forsch/Drug Res.</i> 40(II)(10):1073-1075
C79		Ehrlich, 1989, "Behcet's Disease: Current Concepts," <i>Comprehensive Therapy</i> 15(1):27-30
C80		Elia et al., 1992, "Giant esophageal ulcer treated with steroids in AIDS patient(2)," <i>J. Acquired Immune Defic. Syndr.</i> 5(8):848-849
C81		Eisenbud, L. et al., "Recurrent Aphthous Stomatitis of the Behcet's Type: Successful Treatment with FA Thalidomide", <i>Oral Surgery, oral Medicine, Oral Pathology</i> , Vol. 64; NO. 3, pp. 289-292 (1987)
C82		Eraveily, J. et al., "Thalidomide in Weber-Christian Disease", <i>The Lancet</i> , Vol. 1, No. 8005, p. 251 (1977)
C83		Eriksson, et al., "Drug Exposure and Flow Cytometry Analyses in a Thalidomide Treatment Schedule that Prolongs Rat Cardiac Graft Survival", <i>Transplant Proc.</i> , Vol. 24, No. 6, pp. 2560-2561 (1992)
C84		Eriksson, S. O. et al., "Synthesis and Alkaline Hydrolysis of Some N-substituted Phthalimides", <i>Acta Pharm. Suecica</i> 10:63-84 (1973)
C85		Fabro, S. et al., "The Metabolism of Thalidomide: Some Biological Effects of Thalidomide and its Metabolites", <i>Brit. J. Pharmacol.</i> , Vol. 25, pp. 352-362 (1965)
C86		Fabro, S. et al., "Teratogenic Activity of Thalidomide and Related Compounds", <i>Life Sci.</i> , Vol. 3, pp. 987-992 (1964)
C87		Fabro, S. M.D., "Biochemical Basis of Thalidomide Teratogenicity", <i>The Biochemical Basis of Chemical Teratogenesis</i> , Chapter 5, pp. 159-178 (1981)
C88		Fajardo, et al., "Dual Role of Tumor Necrosis Factor- α in Angiogenesis", <i>Am. J. Pathol.</i> , Vol. 140, No. 3, pp. 539-544 (1992)
C89		Faure, et al., "PMN Leukocytes Chemotaxis: Inhibition by Thalidomide", <i>Pathol. Biol. (Paris)</i> , Vol. 29, No. 10, pp. 601-604 (1981)
C90		Faure, et al., "Inhibition of PMN Leukocytes Chemotaxis by Thalidomide", <i>Arch. Dermatol. Res.</i> , Vol. 269,

	No. 3, pp. 275-280 (1980)
C91	Fazal, N. et al., "Effect of Blocking TNF- α on Intracellular BCG (<i>Bacillus Calmette Guerin</i>) Growth in Human Monocyte-Derived α -acrophages", <i>FEMS Microbiology Immunology</i> , Vol. 105, pp. 337-346 (1992)
C92	Fickentscher, K. et al., "Stereochemical Properties and Teratogenic Activity of Some Tetrahydrophthalimides" <i>Mol. Pharmacol.</i> , Vol. 13, pp. 133-141 (1977)
C93	Field, E. O. et al., "Effect of Thalidomide on Splenomegaly (GVH Reaction) in the Chick Embryo. Treatment of Donor Cells Only", <i>Nature</i> , Vol. 211, No. 5055, pp.-13b9-1310 (1966)
C94	Flohe, L. et al., "Studies on the Hypothetical Relationship of Thalidomide-induced Embryopathy and Collagen Biosynthesis", <i>Arzneimittel/Forschung (Germany west)</i> , Vol. 31, No. 2, pp. 315-320 (1981)
C95	Folkman et al., 1992, "Angiogenesis," <i>J. Biol. Chem.</i> 267(16):10931-10934
C96	Folkman et al., 1983, "Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone," <i>Science</i> 221:719-725
C97	Folkman, J. et al., "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia", <i>Nature</i> Vol. 339, pp. 58-61 (1989)
C98	Folkman, J. et al., "Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy material in Rabbit Thyroid and Canine Intestinal Segment", <i>Annals of Surgery</i> , pp. 491-502 (1966)
C99	Folkman, J., "Tumor Angiogenesis: Therapeutic Implications", <i>The New England J. of Med.</i> , Vol. 285, No. 21, pp. 1182-1186, (1971)
C100	Folkman, J., "Angiogenesis and Its Inhibitors", <i>Important Advances in Oncology</i> , J.B. Lippincott H. Company, pp. 42-62 (1985)
C101	Folkman, J., "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease", <i>Nature Medicine</i> , Vol. 1, No. 1 pp. 27-30 (1995)
C102	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?", <i>J. Natl' Cancer Inst.</i> , Vol. 82 No. 1 (1990)
C103	Francois, J., "Embryological Pigment Epithelial Dystrophies", <i>Ophthalmologica</i> , Vol. 172, pp. 417-433 (1976)
C104	Fuller, et al., "Thalidomide, Peripheral Neuropathy and AIDS", <i>Int. J. STD AIDS</i> , Vol. 2, No. 5, pp. 369-370 (1991)
C105	Furner, B.B., "Treatment of Subacute Cutaneous Lupus Erythematosus", <i>Int. J. Dermatol.</i> , Vol. 29, NO. 8, pp. 542-547 (1990)
C106	Gad et al., "Thalidomide Induces Imbalances in T-Lymphocyte Sub-Populations in the Circulating Blood of Healthy Males", <i>Lepr. Rev.</i> , Vol. 56, No. 1, pp. 35-39 (1985)
C107	Gaetani, "Studi Sull'Attività antitumorale della talidomide," <i>Giornale Italiano di Chemioterapia</i> pp. 83-86
C108	Gehano et al., 1990, "Mouth and pharyngeal hyperalgesic syndromes in AIDS," <i>Ann. Otolaryngol. Chir. Cervicofac</i> 107(5):311-313
C109	Genov et al., 1984, "Treatment of aphthosis with thalidomide and with colchicine," <i>Dermatologica</i> 168(4):182-188
C110	Georgiou et al., 1990, "HIV-associated oesophageal ulcers treated with thalidomide," <i>Med. J. Australia</i> 152:382-383
C111	Gershbein, 1967, "Effect of transplanted tumor and various agents on liver regeneration during pregnancy," <i>P.S.E.B.M.</i> 126:88-92
C112	Gershbein, 1991, "The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas," <i>Cancer Lett.</i> 60:129-133
C113	Gershbein, 1966, "Effect of various agents of liver regeneration and Walker tumor growth in partially hepatectomized rats," <i>Cancer Res.</i> 26(9):1905-1908
C114	Ghigliotti et al., 1993, "Thalidomide: Treatment of choice for aphthous ulcers in patients seropositive for human immunodeficiency virus," <i>J. Am. Acad. Dermatol.</i> 28(2 Part 1):271-272
C115	Gimbrone et al., 1972, "Tumor dormancy in vivo by prevention of neovascularization," <i>J. Exp. Med.</i> 136:261-276
C116	Gimbrone et al., 1974, "Tumor growth and neovascularization: An experimental model using the rabbit cornea," <i>J. Nat. Cancer Institute</i> 52(2):413-419
C117	Goihman-Yahr et al., 1978, "Significance of neutrophil activation in reactional lepromatous leprosy: Effects of thalidomide in vivo and in vitro. Activation in adjuvant disease," <i>Int. Arch. Allergy Appl. Immun.</i> 57:317-332
C118	Goihman-Yahr et al., 1974, "Autoimmune diseases and thalidomide II: Adjuvant disease, experimental allergic encephalomyelitis and experimental allergic neuritis of the rat," <i>Int. J. Leprosy</i> 42(3):266-275
C119	Gorin et al., 1990, "Thalidomide may cure AIDS ulcers," <i>Nurs. Times</i> 86(24):10
C120	Gorin et al., 1990, "Thalidomide in hyperalgesic pharyngeal ulceration of AIDS," <i>Lancet</i> 335:1343
C121	Goulden et al., 1993, "Linear prurigo simulating dermatitis artefacta in dominant dystrophic epidermolysis bullosa," <i>Br. J. Dermatol.</i> 129(4):443-446
C122	Grabstald et al., 1965, "Clinical experiences with thalidomide in patients with cancer," <i>Clin. Pharmacol. and Ther.</i> 6:298-302

C123	Grant et al., 1993, "Scatter factor induces blood vessel formation in vivo," PNAS 90:1937-1941
C124	Grinspan et al., 1989, "Treatment of aphthae with thalidomide," J. Am. Acad. Dermatol. 20(6):1060-1063
C125	Grinspan, 1985, "Significant response of oral aphthosis to thalidomide treatment," Am. Acad. of Dermatol. 12(1, Part 1):85-90
C126	Grosshans et al., 1984, "Thalidomide therapy for inflammatory dermatoses," Int. J. Dermatol. 23(9):598-602
C127	Guidetti et al., 1969, "Ricerche Sull'azione immunodepressiva della talidomide e del prednisolone in ratti portatori di neoplasie sperimentalmente indotte," Cancro 22:503-512
C128	Gunzler, 1992, "Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations," Drug Saf. 7(2):116-134
C129	Gunzler, 1989, "Thalidomide - A therapy for the immunological consequences of HIV infection?" Medical Hypothesis 30(2):105-109
C130	Gutierrez-Rodriguez et al., 1989, "Treatment of refractory rheumatoid arthritis - The thalidomide experience," J. Rheumatol. 16(2):158-163
C131	Gutierrez-Rodriguez et al., 1984, "Thalidomide: A promising new treatment for rheumatoid arthritis," Arthritis and Rheumatism 27(10):1118-1121
C132	Haffner, 1992, "Studies involving orphan products for treating/diagnosing women's diseases," Food and Drug Law J. 48:205-211
C133	Hamza, 1990, "Behcet's Disease, palmoplantar pustulosis and HLA-B27 treatment with thalidomide," Clin. Exp. Rheumatol. 8(4):427
C134	Hamza, 1986, "Treatment of Behcet's disease with thalidomide," Clin. Rheumatol. 5(3):365-371
C135	Handley et al., 1993, "Chronic bullous disease of childhood and ulcerative colitis," Pediatric Dermatol. 10(3):256-258
C136	Handley et al., 1992, "Chronic bullous disease of childhood and ulcerative colitis," Brit. J. Dermatol. 127(Supp. 40):67-68
C137	Harindra et al., 1992, "Papulo-pruritic eruption and giant ulceration of the mouth: A difficult clinical feature to treat in the patient infected with human immunodeficiency virus(1)," Arch. Intern. Med. 152(9):1924
C138	Harris, 1997, "Antiangiogenesis for cancer therapy," Lancet 349(Supp. II):13-15
C139	Hasper, 1983, "Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients," Arch. Dermatol. 19(10):812-815
C140	Hasper et al., 1982, "Thalidomide in the treatment of chronic discoid lupus," Acta. Derm. Venereol. 62(4):321-324
C141	Hastings et al., 1970, "Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities nodosum leprosum," Clin. Pharmacol. Ther. 11(4):481-487
C142	Hatfill et al., 1991, "Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites," Leuk. Res. 15(2/3):129-136
C143	Hayashi et al., 1997, "A synthetic peptide for a chemokines inhibits the growth of melanoma cell lines," J. Clin. Invest. 99(11):2581-2587
C144	Heaton et al., 1992, "Graft-versus-host disease following liver transplantation," J.R. Soc. Med. 85(6):313-314
C145	Hellman et al., 1965, "Prolongation of skin homograft survival by thalidomide," Brit. Med. J. 2:687-389
C146	Helm et al., 1981, "Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide," Arzneim. Forsch./Drug Res. 31(I, No. 6):941-949
C147	Hendler et al., 1983, "Thalidomide for autoimmune disease," Medical Hypotheses 10:437-443
C148	Hendler, "Immune modulators thalidomide," The Oxygen Breakthrough, pp. 217-219
C149	Heney et al., 1991, "Thalidomide treatment for chronic graft-versus-host disease," Brit. J. Haematol. 78:23-27
C150	Heney et al., 1990, "Thalidomide in the treatment of graft-versus-host disease," Biomed. Pharmacother. 44(4):199-204
C151	Heney et al., 1988, "Thalidomide for chronic graft-versus-host disease in children," Lancet 2(8623):1317
C152	Hojyo et al., 1992, "Actinic prurigo (9)," Int. J. Dermatol. 31(5):372-373
C153	Holm et al., 1993, "Chronic cutaneous lupus erythematosus treated with thalidomide," Arch. Dermatol. 129(12):1548-1550
C154	Hori et al., 1991, "Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor," Cancer Res. 51:6180-6184
C155	Hu, 1994, "Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies," Inflammation 18:45-58
C156	Hu et al., 1997, "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells," FASEB J. 11:498-504
C157	Ingber et al., 1990, "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth," Lett. to Nature 348:555-557

C158	Ingber, 1990, "Drug news and trial developments," AIDS Patient Care 6(6):288
C159	Jacobson et al., 1997, "Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection," New Engl. J. Med. 336(21):1487-1493
C160	Jacobson et al., 1976, "The Diagnosis and treatment of leprosy," South Med. J. 69(8):979-985
C161	Jager et al., 1971, "Clinical observations in the treatment of leprosy reaction with cyclic imides," Int. J. Lepr. Other Mycobact. Dis. 39(2):589
C162	Jeltsch et al., 1997, "Hypeplasia of lymphatic vessels in VEGF-C transgeneic mice," Science 276:1423-1426
C163	Jenkins et al., 1985, "Thalidomide, orogenital ulcers, and risk of teratogenicity," Lancet 1(8417-8418):511
C164	Jenkins et al., 1984, "Thalidomide in severe orogenital ulceration," Lancet 2(8417-8418):1424-1426
C165	Jennings et al., 1969, "Effect of actinomycin D on the production of acute phase protein in the rabbit," Experientia 25:305-306
C166	Jew et al., 1990, "Thalidomide in erythema nodosum leprosum, DICP 24(5):482-483
C167	Johnke et al., 1993, "Thalidomide treatment of prurigo nodularis," Ugeskr Laeger 155(38):3028-3030, Abstract
C168	Jonsson, 1972, "Chemical structure and teratogenic properties IV. An outline of a chemical hypothesis for the teratogenic action of thalidomide," Acta Pharm. Succica 9:543-562
C169	Jonsson, 1972, "Chemical structure and teratogenic properties I. Synthesis and teratogenic activity in rabbits of some derivatives of phthalimide, isoindole-1-one, 1,2-benzisothiazoline-3-one-1, 1-dioxide and 4(3II)-quinazoline," Acta Pharm. Succica, 9:431-436
C170	Jonsson, 1972, "Chemical structure and teratogenic properties III. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues," Acta Pharm. Succica 9:521-542
C171	Jorizzo et al., 1986, "Thalidomide effects of behcet's syndrome and pustular vasculitis," Arch. Intern. Med. 146(5):878-881
C172	Juret et al., 1963, "Absece d'effet carcino-frenateur du talidomide vis-à-vis de deux tumeurs greffées," Societe de Biologie 23:246-249
C173	Kaitin, 1991, "Graft-versus-host disease," N. Engl. J. Med. 325(5):357-358
C174	Kaplan et al., 1994, "TNF α regulation of HIV1: Biology and therapy," Res. In Immunol. 145(8-9):685-690
C175	Katsuta et al., 1965, "Carcinogenesis in tissue culture. 3. Effects of the second treatments on DAB-Induced proliferating liver cells of normal rats in culture," Jpn. J. Exp. Med. 35(4):231-248
C176	Keenan et al., 1991, "Immunosuppressive properties of thalidomide," Transplantation 52(5):908-910
C177	Kenyon et al., "The discovery of new inhibitors of angiogenesis using an improved mouse corneal neovascularization model," No. 459-367, pp. S94 (Abstract only)
C178	Kim et al., 1993, "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo," Lett. to Nature 362:841-844
C179	Kitamoto et al., 1997, "Vascular endothelial growth factor is an essential molecule for mouse kidney development: Glomerulogenesis and nephrogenesis," J. Clin. Invest. 99(10):2351-2357
C180	Klug et al., 1994, "Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus," Arch. Toxicol. 68:203-205
C181	Knighton et al., 1977, "Avascular and vascular phases of tumor growth in the chick embryo," Br. J. Cancer 35:347-356
C182	Knop et al., 1983, "Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus," Br. J. Dermatol. 108(4):461-466
C183	Koch et al., 1985, "4 thalidomide and congeners as anti-inflammatory agents," Progress in Medicinal Chem. 22:166-242
C184	Korn et al., 1993, "The second international workshop on scleroderma research," Matrix 13(5):427-429
C185	Kroger et al., 1996, "Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice," Inflammation 20(2):203-215
C186	Kundu et al., 1995, Prurigo nodularis in an HIV positive man (2)," Genitourinary Med. 71(2):129-130
C187	Kurkcuoglu et al., 1985, "Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae," Br. J. Dermatol. 112(5):632
C188	Lane et al., 1990, "Treatment of actinic prurigo with intermittent short-course topical 0.05% clobetasol 17-propionate: A preliminary report," Arch. Dermatol. 126(9):1211-1213
C189	Languillon, 1971, "The effects of thalidomide on leprosy reaction," Int. J. Lepr. Other Mycobact. Dis. 39(2):590-592
C190	Larsson, 1990, "Treatment of severe colitis in behcet's syndrome with thalidomide (CG-217)," J. of Intern. Med. 228:405-407
C191	Ledo, 1993, "Photodermatosis, Part I: Photobiology, photoimmunology, and idiopathic photodermatoses," Int. J. Dermatol. 32(6):387-396
C192	Lehner et al., 1985, "Thalidomide, orogenital ulcers, and the risk of teratogenesis," Lancet 8423:288-289

C193	Lenicque, 1967, "Action of thalidomide on the induction of tentacles in regenerating hydra littoralis," <i>Acta. Zool.</i> 127-139
C194	Levy et al., 1973, "Treatment of erythema nodosum leprosum with thalidomide," <i>Lancet</i> 2(824):324-325
C195	Lien et al., 1970, "The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber," <i>Surgery</i> 68(2):334-340
C196	Lo et al., 1989, "Treatment of discoid lupus erythematosus," <i>Int. J. Dermatol.</i> 28(8):497-507
C197	Londono, 1973, "Thalidomide in the treatment of actinic prurigo," <i>Int. J. Dermatol.</i> 12(5):326-328
C198	Lovell et al., 1983, "Thalidomide in actinic prurigo," <i>Br. J. Dermatol.</i> 108(4):467-471
C199	Lopez et al., 1993, "Thalidomide as therapy for intestinal chronic GVHD," <i>Bone Marrow Transplant.</i> 11(3):251-252
C200	Louzir et al., 1992, "Erythroleucemie chez un patient ayant une maladie de behcet et traite au long cours par thalidomide," <i>Ann. de Med. Interne</i> 143:479-480
C201	Lueprasitsakul et al., 1990, "Effect of thalidomide on the incidence of iodine-induced and spontaneous lymphocytic thyroiditis and spontaneous diabetes mellitus in the BB/Wor rat," <i>Acta Endocrinologica</i> 123:79-83
C202	Luers, 1962, "Failure of mutagenic action of thalidomide in <i>Drosophila</i> ," <i>Lancet</i> II(7258):1332
C203	Magana-Garcia, 1994, "Antimalarials for children," <i>J. Am. Acad. Dermatol.</i> 30(3):510
C204	Maione et al., 1990, "Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides," <i>Science</i> 2:77-78
C205	Makonkawkeyoon et al., 1993, "Thalidomide inhibits the replication of human immunodeficiency virus type 1," <i>PNAS</i> 90:5974-5978
C206	Marin-Padilla et al., 1963, "Thalidomide induced alterations in the blastocyst and placenta of the armadillo, <i>Dasypus novemcinctus Mexicanus</i> , including a choriocarcinoma," <i>Am. J. Pathol.</i> 43(6):999-1016
C207	Mascaro et al., 1979, "Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis," <i>Arch. Dermatol.</i> 115:636-637
C208	Matsubara et al., 1987, "Inhibition of human endothelial cell proliferation by gold compounds," <i>J. Clin. Invest.</i> 79:1440-1446
C209	Matsuyama et al., 1991, "Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?" <i>AIDS</i> 5(12):1405-1417
C210	Mauad, 1963, "Melhoras clinicas obtidas em doentes cancerosos avancados com tratamento pela talidomida associada a hormônios," <i>Anais Paulistas Medicina e Cirurgia</i> pp. 15-39
C211	Maurice et al., 1986, "The effect of thalidomide on arachidonic acid metabolism in human polymorphonuclear leukocytes and platelets," <i>Br. J. Dermatol.</i> 115(6):677-680
C212	McCarthy et al., 1989, "Thalidomide for the therapy of graft-versus-host disease following allogeneic bone marrow transplantation," <i>Biomed. Pharmacother.</i> 43(9):693-697
C213	McKenna et al., 1992, "Linear IgA disease, oral ulceration and Crohn's disease," <i>Br. J. Dermatol.</i> 127:67-68
C214	Meza et al., 1993, "Managing the gastrointestinal complications of AIDS," <i>Drug Therapy</i> 23(11):74-83
C215	Miller et al., 1980, "Zusammentreffen einer thalidomid-induzierten fehlbildung mit einem malignen lymphom hohen malignitätsgrades," <i>Monatsschr. Kinderheilkd.</i> 128:27-29
C216	Miller et al., 1987, "Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission," <i>Int. J. Lepr. Other Mycobact. Dis.</i> 55(3):441-449
C217	Misery et al., 1993, "Remission of Langerhans cell histiocytosis with thalidomide treatment," <i>Clin. Exp. Dermatol.</i> 18(5):487
C218	Miura et al., 1970, "Potentiating effect of thalidomide on methylcholanthrene oncogenesis in mice," <i>Experientia</i> 26(Fasc. 3):305-306
C219	Miyachi, 1985, "A possible mechanism of actions of thalidomide on rheumatoid arthritis," <i>Arthritis Rheumatol.</i> 28(7):836
C220	Miyachi et al., 1982, "Effects of thalidomide on the generation of oxygen intermediates by Zymosan-stimulated normal polymorphonuclear leukocytes," <i>Arch. Dermatol. Res.</i> 274(3-4):363-367
C221	Mohri et al., 1968, "Negative effect of thalidomide and relative substances on the growth of HeLa cells," <i>Chem. Pharm. Bull.</i> 16:2289-2292
C222	Moncada et al., 1985, "Thalidomide - effect on T Cell subsets as a possible mechanism of action," <i>Int. J. Lepr. Other Mycobact. Dis.</i> 53(2):201-205
C223	Montruccio et al., 1994, "Tumor necrosis factor α -induced angiogenesis depends on in situ platelet-acting factor biosynthesis," <i>J. Exp. Med.</i> 180:377-382
C224	Moulin et al., 1983, "Treatment of Jessnet-Kanof disease with thalidomide," <i>Ann. Dermatol. Venereol.</i> 10(8):611-614
C225	Mshana et al., 1982, "Thymus-dependent lymphocytes in leprosy II. Effect of chemotherapy on T-lymphocyte subpopulations," <i>J. Clin. Immunol.</i> 2(2):69-74

C226	Muckter et al., 1965, "Thalidomide and tumor," Antimicrobial Agents and Chemother. pp. 531-538
C227	Mummery et al., 1983, "Screening for cytotoxicity in neuroblastoma cells-I. Dependence of growth inhibition of the presence of serum," Toxicity Lett. 18:201-209
C228	Munro et al., 1988, "Pyoderma gangrenosum associated with Behcet's syndrome-response to thalidomide," Clin. Exp. Dermatol. 13(6):408-410
C229	Muthukkaruppan et al., 1979, "Angiogenesis in the mouse cornea," Science 205(28):1416-1418
C230	Naafs et al., 1985, "Thalidomide therapy an open trial," Intl. J. Dermatol. 24(2):131-134
C231	Naafs, 1996, "Bangkok workshop on leprosy research. Treatment of reactions and nerve damage." Int. J. Lepr. Other Mycobact. Dis. 64(4, Supp.):S21-28
C232	Neubert, "Teratogenicity: Any relationship to carcinogenicity?" Instit. Toxicity Embryopharmacol., Free Univ. Berlin, Berlin, Federal Rep. of Germany, pp. 169-178
C233	Nguyen et al., 1993, "Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients," J. Natl. Cancer Inst. 85(3):241-242
C234	Nguyen et al., 1994, "Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of patients with a wide spectrum of cancers," J. Natl. Cancer Inst. 86(5):356-361
C235	Nicolas et al., 1989, "Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus," New Engl. J. Med. 321(22):1550-1551
C236	Nicolau et al., 1990, "Thalidomide: Treatment of severe recurrent aphthous stomatitis in patients with AIDS," DICP 24(11):1054-1056
C237	Nielsen et al., 1986, "Thalidomide enhances superoxide anion release from human polymorphonuclear and leukocytes," Acta. Pathol. Microbiol. Immunol. Scand. [C], 94(6):233-237
C238	Obeso et al., 1990, "Methods in laboratory investigation: A hemangioendothelioma-derived cell line: Its use as a model for the study of endothelial cell biology," Lab. Invest. 63(2):259-269
C239	Oikawa et al., 1991, "Eponemycin, a novel antibiotic is a highly powerful angiogenesis inhibitor," Biochem. Biophys. Res. Comm. 181(3):1070-1077
C240	Olson et al., 1965, "Thalidomide (N-phthaloylglutamide) in the treatment of advanced cancer," Clin. Pharmacol. Ther. 6(3):292-297
C241	Orzalesi, 1992, "Il Danno iatrogeno in neonatologica," Ped. Med. Chir. 14:105-112
C242	Ostraat et al., 1992, "Thalidomide prolongs graft survival in rat cardiac transplants," Transplant. Proc. 24(6):2624-2625
C243	Otsuka et al., 1991, "A new potent angiogenesis inhibitor, FR-118487," J. Microbiol. Biotechnol. 1(3):163-168
C244	Paller et al., 1992, "Proceedings of the concurrent sessions," Pediatr. Dermatol. 9(4):397-406
C245	Passaniti et al., 1992, "Methods in laboratory investigation: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor," Lab. Invest. 67(4):519-528
C246	Patey et al., 1989, "Thalidomide et colite ulcereuse dans la maladie de Behcet,"Gastronenterol. Clin. Biol. 13:104-110
C247	Pearson et al., 1969, "Treatment of moderately severe erythema nodosum leprosum with thalidomide - A double-blind controlled trial," Lepr. Rev. 40(2):111-116
C248	Peyron et al., "The pharmacological basis for the treatment of photodermatoses," Biochimie 68(6):899-904
C249	Pfordte, 1971, "Über die beeinflussung des serumproperdinsystems durch verschiedene arzneimittel," Pharmazie 26:301-302
C250	Phillips et al., 1996, "Tumor necrosis factor alpha (rhTNF) fails to stimulate angiogenesis in the rabbit cornea," Anatomical Rec. 245:53-56
C251	Powell et al., 1985, "Investigation and treatment of orogenital ulceration; studies on a possible mode of action of thalidomide," Brit. J. Dermatol. 113(Supp. 28):141-144
C252	Prignet et al., 1983, "Sarcoidose cutanee traitement par la thalidomide," La Presse Medicale 12(47):3007
C253	Proenca, "Thalidomide: An eclectic medication in dermatology," Rev. Paul. Med. 107(1):41-46 (Abstract)
C254	Radeff et al., 1990, "Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: Successful treatment with thalidomide," J. Am. Acad. Dermatol. 23(3, pt. 1):523-525
C255	Rainsford, 1990, "Disease-modifying antirheumatic and immunoregulatory agents," Bailliere's Clin. Rheumatol. 4(3):405-432
C256	Rajan et al., 1983, "A clinical study of thalidomide comparing pre-treatment and post-treatment reactional episodes and corticosteroid requirements," Lepr. India 55(1):111-116
C257	Randall, 1990, "Investigational new drug (US) 'orphan' trials now use thalidomide from two source," JAMA 263(11):1474
C258	Randall, 1990, "Thalidomide's back in the news, but in more favorable circumstances," JAMA 263(11):1467-1468
C259	Revuz, 1990, "Actualite du thalidomide," Ann. Dermatol. Venereol. 117:313-321

C260	Revuz et al., 1990, "Crossover study of thalidomide vs. placebo in severe recurrent aphthous stomatitis," Arch. Dermatol. 126:923-927
C261	Rhoton, 1993, "Role for thalidomide in primary biliary cirrhosis treatment?" Gastroenterol. 105(3):956
C262	Robbins, "The plasminogen-plasmin enzyme system," Fibrinolysis pp. 340-357
C263	Roe, 1963, "Pathology thalidomide and neoplasia," Nature 200:1016-1017
C264	Roe et al., 1965, "Tumour-incidence in progeny of thalidomide-treated mice," Brit. J. Cancer pp. 331-333
C265	Ruggenini et al., 1967, "Talidomide e tumori sperimentali," Cancro 20:39-55
C266	Rustin et al., 1990, "Pyoderma gangrenosum associated with Behcet's disease: Treatment with thalidomide," J. Am. Acad. Dermatol. 23(5, pt. 1):941-944
C267	Ryan et al., 1992, "Thalidomide to treat esophageal ulcer in AIDS (6)," New Engl. J. Med. 327(3):208-209
C268	Salven et al., 1997, "Serum vascular endothelial growth factor is often elevated in disseminated cancer," Clin. Cancer Res. 3:647-651
C269	Sampaio et al., 1992, "Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum patients," J. Exp. Med. 175(6):1729-1737
C270	Sampaio et al., 1991, "Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes," J. Exp. Med. 173(3):699-703
C271	Santis, 1991, "Aphthous stomatitis and its management," Curr. Opin. Dent. 1(6):763-768 (Abstract)
C272	Santos et al., 1993, "In vitro tumor necrosis factor production by mononuclear cells from lepromatous leprosy patients and from patients with erythema nodosumleprosum," Clin. Immunol. Immunopathol. 67(3):199-203
C273	Sato et al., 1997, "Increased concentration of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules," J. Clin. Endocrinol. Metabol. 82(6):1968-1972
C274	Schweigerer et al., 1992, "Angiogenesis and angiogenesis inhibitors in paediatric diseases," European J. Pediatr. 151:472-476
C275	Shannon et al., 1981, "Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy," Scand. J. Immunol. 13(6):553-562
C276	Shannon et al., 1992, "Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood," Lepr. Rev. 63(1):5-11
C277	Shealy et al., 1965, "D- and L-Thalidomide," Chem. and Indust. pp. 1030-1031
C278	Sheehan, 1986, "Thalidomide neurotoxicity and rheumatoid arthritis," Arthritis and Rheum. 29(10):1296
C279	Sherman et al., 1986, "Thalidomide: A twenty-five year perspective," Food Drug Cosmetic Law J. 41:458-466
C280	Sheskin, 1980, "The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide," Int. J. Dermatol. 19(6):318-322
C281	Sheskin et al., 1981, "In vivo measurements of iron, copper, and zinc in the skin of prurigo nodularis patients treated with thalidomide," Dermatologica 162(2):86-90
C282	Shi et al., 1991, "Kringle domains and plasmin denaturation," Biochem. Biophys. Res. Comm. 178(1):360-368
C283	Sidky et al., 1987, "Inhibition of angiogenesis by interferons: Effect on tumor and lymphocyte-induced vascular responses," Cancer Res. 47:5155-5161
C284	Sliverman, 1980, "Medical inflation," Persp. Biol. Med. pp. 617-637
C285	Smith et al., "Studies on the relationship between the chemical structure and embryotoxic activity of thalidomide and related compounds," Chem. Struct. and Embryopathy pp. 194-209
C286	Srivastava et al., 1988, "The prognostic significance of tumor vascularity in intermediate-thickness skin melanoma," Am. J. Pathol. 133:419-423 (Abstract from Medline Accession No.: 06745734)
C287	Style, 1995, "Early diagnosis and treatment of leprosy in the United States," Am. Family Phys. 52(1):172-178
C288	Sugiura et al., 1964, "Effect of thalidomide on transplantable mouse, rat, and hamster tumors," GANN 55:57-60
C289	Suzuki, "The history of iatrogenic diseases in Japan," First Dept. Internal Med., Univ. Environ. Occup. Health, Kitakyushu, Japan pp. 35-40
C290	Swift, 1973, "Thalidomide in erythema nodosum leprosum," Lancet 2(835):966
C291	Szydlowska et al., 1978, "On the application of thalidomide as a block of functional groups of proteins in histochemical investigations," Folia Histo. Cytochem. 16(3):233-240
C292	Tamura et al., 1990, "Combination thalidomide and cyclosporine for cardiac allograft rejection. Comparison with combination methylprednisolone and cyclosporine," Transplantation 49(1):20-25
C293	Tanaka et al., 1997, "Vascular endothelial growth factor in diabetic retinopathy," Lancet 349:1520
C294	Taylor et al., 1982, "Protamine is an inhibitor of angiogenesis," Nature 297:307-312
C295	Teppo et al., 1977, "Thalidomide-type malformations and subsequent osteosarcoma," Lancet II(8034):405
C296	"Thalidomide 20 years on," Lancet II(8245):510-511 (1981)

C297	"Thalidomide," Merch Index, 11 th ed., pp. 1458 (1989)
C298	Theophilus, 1980, "Treatment with thalidomide in steroid dependency and neuritis," Lepr. India 52(3):423-428
C299	Thomas et al., 1972, "Effect of thalidomide on liver regeneration in rat," Indian J. Exp. Biol. 10:314-315
C300	Thomas et al., 1972, "Lack of thalidomide induced aplasia in regenerating tail of lizard, hemidactylus flaviviridis," Indian J. Exp. Biol. 10:316-317
C301	Thomas et al., 1993, "Successful treatment of adult's langerhans cell histiocytosis with thalidomide," Arch. Dermatol. 129:1261-1264
C302	Torry et al., 1992, "Angiogenesis in the uterus: Potential regulation and relation to tumor angiogenesis," Am. J. Reproductive Immunol. 27:171-179
C303	Traldi et al., 1965, "L'impiego dell'imide dell'acido n'ftalilglutammico (Talidomide) nella terapia sintomatica del vomito di molti pazienti affetti da neoplasie maligne o causato dalla somministrazione di cloridato di mecloretamina," Cancro 18:336-341
C304	Trautman, 1976, "Treatment of Hansen's Disease," Cutis 18(1):62-65
C305	Van den Broek, 1980, "Treatment of prurigo nodularis with thalidomide," Arch. Dermatol. 116(5):571-572
C306	Vasilescu et al., 1968, "Cercetari privind actiunea talidomidei asupra celulelor cultivate in vitro," Cerc. Fiziol. 13(4):293-300
C307	Verhaul et al., 1999, "Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits," Brit. J. Cancer 79(1):114-118
C308	Vicente et al., 1993, "In vitro activity of thalidomide against mycobacterium avium complex," Arch. Internal Med. 153:334
C309	Villa et al., 1963, "Antimytotic effect of thalidomide and its metabolites on the chick embryo blood cells," Haematol. Latina 6:217-221
C310	Villa et al., 1963, "Cytological effects of thalidomide," Lancet pp. 725
C311	Vladutiu, 1966, "Another chance for thalidomide?" Lancet I(7444):981-982
C312	Vogelsang et al., 1992, "Thalidomide for the treatment of chronic graft-versus-host disease," New Engl. J. Med. 326:1055-1059
C313	Vogelsang et al., 1989, "Therapy of chronic graft-versus-host disease in a rat model," Blood 74(1):507-511
C314	Vogelsang et al., 1987, "Thalidomide induction of bone marrow transplantation tolerance," Transplant. Proc. 19(1, Pt. 3):2658-2661
C315	Vogelsang et al., 1986, "Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model," Transplantation 41(5):644-647
C316	Vogt et al., 1997, "Inhibition of angiogenesis in Kaposi's sarcoma by Captopril," Lancet 349:1148
C317	Waters et al., 1979, "Treatment of ulcerative colitis with thalidomide," Brit. Med. J. 1(6166):792
C318	Waters, 1991, "Use of thalidomide in leprosy," BMJ 303(6800):470
C319	Waters, 1971, "An internally-controlled double-blind trial of thalidomide in severe erythema nodosum leprosum," Lepro. Rev. 42(1):26-42
C320	Weidner et al., 1991, "Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma," The New Engl. J. Med. 324(1):1-8
C321	Weidner et al., 1993, "Tumor angiogenesis correlates with metastasis in invasive prostate cancer," Am. J. Pathol. 143(2):401-409
C322	Weidner et al., 1992, "Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma," J. Nat. Cancer Inst. 84(24):1875-1887
C323	Weslowski et al., "Effect of light on a murine model of retinopathy of prematurity," Invest. Ophthalmol. & Visual Science 33(4):1281 (Abstract)
C324	White et al., 1989, "Treatment of pulmonary hemangiomatosis with recombinant interferon alpha-2a," New Engl. J. Med. 32(18):1197-1200
C325	Williams, 1990, "Enantiomers in arthritic disorders," Pharmacol. & Therapeutics 46(2):273-295
C326	Williams et al., 1991, "Thalidomide hypersensitivity in AIDS," Lancet 337:436-437
C327	Winkelmann et al., 1984, "Thalidomide treatment of prurigo nodularis," Acta. Derm. Venereol. 64(5):412-417
C328	Wood et al., 1990, "The potential use of thalidomide in the therapy of graft-versus-host disease - A review of clinical and laboratory information," Leuk. Res. 14(5):395-399
C329	Woodyatt, 1962, "Thalidomide," Lancet pp. 750
C330	Wulff et al., 1985, "Development of polyneuropathy during thalidomide therapy," Br. J. Dermatol. 112(4):475-480
C331	Yazici et al., 1991, "Practical treatment recommendations for pharmacotherapy of Behcet's syndrome," Drugs 42(5):796-804
C332	Yoshimura et al., 1993, "Cloning, sequencing, and expression of human macrophage stimulating protein (MSP,

		MSTI) confirms MSP as a member of the family of Kringle proteins and locates the MSP gene on chromosome 3," J. Biol. Chem. 268(21):15461-15468
	C333	Youle et al., 1989, "Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody," BMJ 298(6671):432
	C334	Youle et al., 1990, "Thalidomide in hyperalgetic pharyngeal ulceration of AIDS," Lancet 335(8705):1591
	C335	Yue et al., 1997, "2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: Possible role for stress-activated protein kinase signaling pathway and Fas expression," Molecular Pharmacol. 51:951-962
	C336	Ziche et al., 1997, "Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis," J. Clin. Invest. 99(11):2625-2634
	C337	Zwart, 1966, "Treatment of grade II astrocytoma with thalidomide," Arzneim. Forsch. 16(12):1688-1689

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	